What’s Emergent BioSolutions Inc. (EBS) Upside After Reaching 52-Week High?

June 15, 2018 - By Louis Casey

Emergent BioSolutions Inc. (NYSE:EBS) Logo

Investors sentiment decreased to 1.77 in Q1 2018. Its down 0.25, from 2.02 in 2017Q4. It fall, as 10 investors sold Emergent BioSolutions Inc. shares while 65 reduced holdings. 56 funds opened positions while 77 raised stakes. 38.34 million shares or 3.95% more from 36.89 million shares in 2017Q4 were reported.
Caprock Group reported 5,558 shares stake. Gsa Capital Llp has invested 0.29% in Emergent BioSolutions Inc. (NYSE:EBS). Swiss National Bank & Trust invested in 61,100 shares or 0% of the stock. Eqis Mngmt Inc invested 0.14% in Emergent BioSolutions Inc. (NYSE:EBS). Putnam Investments, a Massachusetts-based fund reported 41,254 shares. Fil holds 0.02% in Emergent BioSolutions Inc. (NYSE:EBS) or 139,796 shares. Dupont Mngmt Corp invested 0.02% in Emergent BioSolutions Inc. (NYSE:EBS). Plante Moran Advisors Ltd Liability owns 17 shares. Nordea Invest Management Ab owns 106,861 shares. Pitcairn holds 0.03% or 5,814 shares in its portfolio. Employees Retirement System Of Texas reported 116,000 shares. Mason Street Advsrs Ltd Liability Corporation accumulated 9,731 shares or 0.01% of the stock. Zacks Inv Mgmt holds 0.02% or 20,433 shares in its portfolio. 4,905 were accumulated by Howe & Rusling. Dubuque National Bank & Trust And Tru stated it has 0% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS).

Since January 2, 2018, it had 0 insider buys, and 11 sales for $4.28 million activity. 5,000 shares valued at $264,448 were sold by JOULWAN GEORGE A on Monday, June 11. 7,893 shares were sold by Richard Ronald, worth $434,115. On Tuesday, June 5 Abdun-Nabi Daniel sold $822,615 worth of Emergent BioSolutions Inc. (NYSE:EBS) or 15,785 shares. 7,729 Emergent BioSolutions Inc. (NYSE:EBS) shares with value of $391,787 were sold by Hauer Jerome M. $19,857 worth of stock was sold by Zoon Kathryn C on Wednesday, June 6.

The stock of Emergent BioSolutions Inc. (NYSE:EBS) hit a new 52-week high and has $54.50 target or 4.00 % above today’s $52.40 share price. The 9 months bullish chart indicates low risk for the $2.61B company. The 1-year high was reported on Jun, 15 by Barchart.com. If the $54.50 price target is reached, the company will be worth $104.44M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock decreased 5.82% or $3.24 during the last trading session, reaching $52.4. About 183,150 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has risen 65.53% since June 15, 2017 and is uptrending. It has outperformed by 52.96% the S&P500.

Analysts await Emergent BioSolutions Inc. (NYSE:EBS) to report earnings on August, 2. They expect $1.02 earnings per share, up 684.62 % or $0.89 from last year’s $0.13 per share. EBS’s profit will be $50.82M for 12.84 P/E if the $1.02 EPS becomes a reality. After $-0.03 actual earnings per share reported by Emergent BioSolutions Inc. for the previous quarter, Wall Street now forecasts -3,500.00 % EPS growth.

Emergent BioSolutions Inc. (NYSE:EBS) Ratings Coverage

Among 5 analysts covering Emergent BioSolutions (NYSE:EBS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Emergent BioSolutions has $6200 highest and $55 lowest target. $59’s average target is 12.60% above currents $52.4 stock price. Emergent BioSolutions had 5 analyst reports since January 24, 2018 according to SRatingsIntel. On Monday, June 11 the stock rating was initiated by Cantor Fitzgerald with “Buy”. The stock of Emergent BioSolutions Inc. (NYSE:EBS) earned “Buy” rating by Singular Research on Tuesday, February 27. As per Tuesday, April 24, the company rating was downgraded by Wells Fargo.

More notable recent Emergent BioSolutions Inc. (NYSE:EBS) news were published by: Globenewswire.com which released: “Consolidated Research: 2018 Summary Expectations for PGT, National Commerce, CrossAmerica Partners LP …” on May 24, 2018, also Benzinga.com with their article: “Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth” published on June 13, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on June 12, 2018. More interesting news about Emergent BioSolutions Inc. (NYSE:EBS) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For June 13, 2018” published on June 13, 2018 as well as Globenewswire.com‘s news article titled: “Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility” with publication date: June 07, 2018.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.61 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 30.72 P/E ratio. The companyÂ’s marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

Emergent BioSolutions Inc. (NYSE:EBS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: